Gustave Roussy

Recognized as Europe’s leading cancer center, Gustave Roussy brings together, on a single site, a hospital, a cutting-edge research institute, and a cancer education school, uniting 3,000 professionals. The institute’s distinction lies in its emphasis on therapeutic innovation, the advancement of precision oncology, and the integration of translational research to accelerate the development and clinical application of novel treatments.

Role within SCALPEL

Cell Studies and In Vitro Validation: GR will focus on the assessment of SCALPEL compound-associated cell death and its mechanism. Moreover, GR will study the hallmarks of immunogenic cell death induced by SCALPEL compounds.